Xtalks Event Header

Register here to receive the On Demand Archive

Speakers for this Event: 

  • Dhiraj Narula, MD, MRCP UK, DM Card, FACC, FISE, Medical Director, Quintiles Cardiac Safety Services
  • J. Rick Turner, PhD, Senior Director, Quintiles Integrated & Translational Cardiovascular Safety
  • Jared Schettler, MS, Director, Quintiles Phase I Biostatistics

                                        Sponsor Logo

This webinar will provide insight into the latest scientific and regulatory thinking around the use of early-phase QT data and concentration QT modeling as a predictor of cardiac risk, ultimately improving decisions about further development and future study design.

With increasing research and development costs and declining pipeline success, pharmaceutical companies need to be more discerning in early development by maximizing the data and insights gleaned in Phase I/IIa studies. Through evolving techniques and methods, researchers are exploring new ways to obtain more robust data before proceeding to larger, late-stage trials.

One such approach is through conducting more rigorous cardiac safety assessments in early Phase I trials. The cardiac safety regulatory landscape requires assessment of an investigational drug's proarrhythmic liability, currently operationalized as drug-induced QT/QTc interval prolongation. While rigorous QT/QTc measurements are taken in the Thorough QT/QTc (TQT) study, it is not typically conducted until relatively late in Phase II clinical development. However, more rigorous assessments in early Phase I trials can be very valuable in scenarios involving both "no-go" and "go" decisions. Reliable observation of an unacceptable degree of QT/QTc interval prolongation can enable an earlier, less costly "no-go" decision. Additionally, if a “go” decision is made, the initial data permits subsequent studies to be designed in the most resource-efficient manner while preserving full scientific integrity.

A good initial understanding of the degree of drug-induced QT/QTc prolongation, and also the variability in such prolongation seen among subjects, enables the TQT to be designed with the minimum necessary number of subjects, leading to a less expensive and shorter study, hence a shorter overall clinical development program.

*************

Access to this archive is given on the understanding that you agree to the provision of your contact information to Xtalks sponsors and partners. Only primary contact information will be shared and this information will only be shared for the purposes of providing relevant offers. This registration form is an application only. Xtalks has the right to refuse access.

If you require help with your registration or have any questions you may contact Xtalks at: email: register@xtalks.com; phone: 416-977-6555, x 371.

By completing this registration form, you agree that the information you have provided is true and accurate.

(note: fields with marked "*" are required)

Email: *
Phone: *
First Name: *
Last Name: *
Organization: *
Job Title: *
Country:*
How did you hear about this webinar? *
When do you start collecting rigorous ECG data in clinical development?
What techniques are you using to build your drug’s Integrated Cardiac Safety profile?
Other (per question above):
Refer this archive to my colleagues:   Enter unlimited emails
Questions/comments for our speakers: